Sipai Health Technology Co, Ltd

Sipai Health Technology maintains a strong liquidity position with a current ratio of 1.83 and cash and equivalents of CNY 259.15 million, which is well above the industry median. The company's price-to-book ratio of 1.09 suggests a market valuation in line with its tangible book value, indicating a relatively stable capital structure. The company's profitability metrics are concerning, with a negative return on equity of -13.27% and a negative return on assets of -7.75%. These figures fall significantly below the industry median for Drug Retailers, highlighting a need for operational improvements to enhance profitability. Sipai Health Technology's revenue is distributed across three segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business. The company's geographic exposure is not disclosed in the input data, but the lack of revenue concentration by region suggests a diversified geographic footprint. The company's growth trajectory is mixed. While the most recent actual revenue of CNY 4.71 billion is a positive indicator, the net income remains negative at CNY -124.27 million. The outlook for the current fiscal year does not provide specific numeric deltas, but the company must address its operating losses to achieve sustainable growth. Risk factors for Sipai Health Technology include its negative net income and operating income, which could affect its ability to meet financial obligations. The company has a low dilution risk, with no immediate filing-based dilution flags detected. The debt-to-equity ratio of 0.02 indicates a conservative capital structure, reducing credit risk. Recent events include the latest actual EPS of -CNY 0.40 and revenue of CNY 4.71 billion. These figures reflect the company's ongoing challenges in achieving profitability and suggest a need for strategic adjustments to improve financial performance.